A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

Journal of Dermatological Treatment

Volumn 27, Issue 4, 2016, Pages 332-338

  Bissonnette, Robert ^a   Luchi, Monica ^b,e   Fidelus Gort, Rosanne ^b,d   Jackson, Shawnta ^b   Zhang, Haifeng ^b   Flores, Robert ^b   Newton, Robert ^b   Scherle, Peggy ^b   Yeleswaram, Swamy ^b   Chen, Xuejun ^b   Menter, Alan ^c  

^a INNOVADERM RESEARCH   (Canada)

^b Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

^e Mesoblast Limited   (Australia)

Author keywords

Cytokine; inflammation; JAK STAT; phase 2; psoriasis vulgaris; tyrosine kinase

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ITACITINIB; PLACEBO; AZETIDINE DERIVATIVE; ISONICOTINIC ACID; JAK1 PROTEIN, HUMAN; JANUS KINASE 1;

ADULT; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY SURFACE; CHRONIC PLAQUE PSORIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; INFESTATION; INSTITUTIONAL REVIEW; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

ADULT; AGED; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISONICOTINIC ACIDS; JANUS KINASE 1; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84954227730     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2015.1115819     Document Type: Article

References (24)

1. R.Parisi, D.P.Symmons, C.E.Griffiths,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
2. X.T.Lima, R.Minnillo, J.M.Spencer, A.B.Kimball Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program Participants. J Eur Acad Dermatol Venereol. 2013;27:680–5.
3. N.Weigle, S.McBane Psoriasis. Am Fam Physician. 2013;87:626–33.
4. C.E.Griffiths, J.N.Barker Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71.
5. M.P.Schon, W.H.Boehncke Psoriasis. N Engl J Med. 2005;352:1899–912.
6. L.Hsu, A.W.Armstrong JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014;2014:283617.
7. T.Kisseleva, S.Bhattacharya, J.Braunstein, C.W.Schindler Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1–24.
8. F.O.Nestle, D.H.Kaplan, J.Barker Psoriasis. N Engl J Med. 2009;361:496–509.
9. Data on File. Incyte Corporation, Wilmington, DE. 2012.
10. P.I.Spuls, L.L.Lecluse, M.L.Poulsen,. How good are clinical severity and outcome measures for psoriasis? quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130:933–43.
11. T.Fredriksson, U.Pettersson Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.
12. K.A.Papp, M.A.Menter, M.Abe,. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomised, placebo-controlled, phase 3 trials. Br J Dermatol. 2015;173:949–61.
13. H.Bachelez, P.C.van de Kerkhof, R.Strohal,. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552–61.
14. K.Ghoreschi, A.Laurence, J.J.O'Shea Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–87.
15. E.B.Lee, R.Fleischmann, S.Hall,. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.
16. N.Punwani, P.Scherle, R.Flores,. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67:658–64.
17. W.C.Ports, S.Khan, S.Lan,. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169:137–45.
18. A.Menter, S.K.Tyring, K.Gordon,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.
19. J.H.Saurat, G.Stingl, L.Dubertret,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–66.
20. C.L.Leonardi, J.L.Powers, R.T.Matheson,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.
21. K.A.Papp, S.Tyring, M.Lahfa,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12.
22. K.A.Papp, A.Menter, B.Strober,. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–77.
23. A.Menter, C.E.Griffiths Current and future management of psoriasis. Lancet. 2007;370:272–84.
24. A.Menter, N.J.Korman, C.A.Elmets,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.